Disease · MONDO_0005282

cutaneous lupus erythematosus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cutaneous lupus erythematosus. Diseases, record MONDO_0005282. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005282

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cutaneous lupus erythematosus; Open Targets
Open Targets ID: MONDO_0005282; Open Targets
Other names: Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Cutaneous, Subacute, Lupus Erythematosus, Subacute Cutaneous; Open Targets
Disease Ontology: DOID:0050169; Disease Ontology
MeSH: D008178; MeSH
NCI Thesaurus: C26819; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 34 drugs, from PMDA; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HYDROXYCHLOROQUINE SULFATE	CHEMBL1690	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
LITIFILIMAB	CHEMBL3833308	Antibody	Phase 3	ClinicalTrials.gov and TTD	5	3	3	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SIRUKUMAB	CHEMBL1743071	Antibody	Phase 3	TTD	2	1	1	Drugs and targets
ANIFROLUMAB	CHEMBL2364653	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ENPATORAN	CHEMBL4802159	Small molecule	Phase 2	ClinicalTrials.gov	4	3	3	Drugs and targets
EDECESERTIB	CHEMBL5095097	Small molecule	Phase 2	ClinicalTrials.gov	3	2	2	Drugs and targets
NIACINAMIDE	CHEMBL1140	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ECLITASERTIB	CHEMBL4861471	Small molecule	Phase 2	ClinicalTrials.gov and TTD	3	1	1	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets37

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TLR7	Toll-like receptor 7	4	Toll-like receptor 7 agonist; Toll-like receptor 7 antagonist; Toll-like receptor 7 inhibitor	Approval	https://conductscience.org/library/genes/51284	Drugs and targets
TYK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets
CD28	T-cell-specific surface glycoprotein CD28	2	T-cell-specific surface glycoprotein CD28 agonist; T-cell-specific surface glycoprotein CD28 antagonist	Phase 2	https://conductscience.org/library/genes/940	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 2	https://conductscience.org/library/genes/3718	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 1/2	https://conductscience.org/library/genes/2908	Drugs and targets
PDE4A	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 2	https://conductscience.org/library/genes/5142	Drugs and targets

1 to 10 of 37

See all 37 targets

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02265744	Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus	Phase 2	730	2019-01-04	Lupus	LULIZUMAB PEGOL	Its record names the disease	ClinicalTrials.gov
NCT05162586	The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)	Phase 2	456	2025-12-01	Systemic Lupus Erythematosus	ENPATORAN	Its record names the disease	ClinicalTrials.gov
NCT02847598	Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)	Phase 2	264	2023-05-15	Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus	LITIFILIMAB	Its record names the disease	ClinicalTrials.gov
NCT04781816	Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus	Phase 2	78	2024-06-24	Cutaneous Lupus Erythematosus	ECLITASERTIB	Its record names the disease	ClinicalTrials.gov
NCT04857034	A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)	Phase 2	74	2025-09-10	Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous	DEUCRAVACITINIB	Its record names the disease	ClinicalTrials.gov
NCT02270957	Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches	Phase 2	66	2020-11-25	Systemic Lupus Erythematosus	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT03134222	Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)	Phase 2	47	2020-04-08	Cutaneous Lupus Erythematosus	FILGOTINIB, LANRAPLENIB	Its record names the disease	ClinicalTrials.gov
NCT03288324	Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus	Phase 1/2	13	2024-07-30	Cutaneous Lupus, Systemic Lupus Erythematosus	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT00708916	Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients	Phase 1/2	8	2021-03-03	Discoid Lupus Erythematosus	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT05048238	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus	Phase 1	7	2025-03-21	Cutaneous Lupus	TOFACITINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SAR443122 vs Placebo: deaths from any cause	0 of 38	0 of 40	78	NCT04781816	Trial comparisons
SAR443122 vs Placebo: serious adverse events	0 of 38	1 of 40	78	NCT04781816	Trial comparisons
Abatacept vs Placebo: 4 Point Improvement in the SLE Disease Activity Index (SLEDAI)	9 of 31	8 of 35	66	NCT02270957	Trial comparisons
Abatacept vs Placebo: SLE Responder Index-4 (SRI-4)	9 of 31	8 of 35	66	NCT02270957	Trial comparisons
Abatacept vs Placebo: British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)	8 of 31	8 of 35	66	NCT02270957	Trial comparisons
Abatacept vs Placebo: deaths from any cause	0 of 31	0 of 35	66	NCT02270957	Trial comparisons
Abatacept vs Placebo: serious adverse events	6 of 31	4 of 35	66	NCT02270957	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42107375	DERIVED	1	PubMed
42107374	DERIVED	1	PubMed
41136221	DERIVED	1	PubMed
37148249	DERIVED	1	PubMed
36069871	DERIVED	1	PubMed
35939578	DERIVED	1	PubMed
35390178	DERIVED	1	PubMed
34498056	DERIVED	1	PubMed
33687069	DERIVED	5	PubMed
32335844	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005282

GET https://conductscience.org/api/diseases/v1/MONDO_0005282/drugs?page=2

API reference For AI assistants